Help and Hope - NICA's Locators Connect Thousands with Life-Saving Therapies
At the beginning of this year, NICA's Infusion Center Locator scaled quickly help individuals find care sites administering antibody therapies for COVID-19. After publishing antibody therapy sites in over 24 states, we decided to expand and leverage this well-loved resource by creating a dedicated COVID-19 Antibody Therapy Locator.

Want to know more?
EUAs, NICA, and FYIs for Administering COVID-19 Antibody Therapies
With several COVID-19 antibody therapies receiving Emergency Use Authorization (EUA) from the FDA, NICA worked closely with pharmaceutical manufacturers and governmental partners at "The Operation" (previously, Operation Warped Speed) to ensure the providers we serve had resources to prescribe and administer these products safely and appropriately. We developed materials to help promote safe, efficient, and responsible use of COVID-19 therapies.
New Year, New and Improved Provider Membership Structure
We are excited to now offer infusion providers Supporting and Elite membership options that give you the freedom to sign up for the benefits that best meet your needs. If you aren't already seated at the table, sign your office(s) up today. We look forward to welcoming you into the NICA family!
The NICA Family Grows: New Advisory Committee Members Bring Fresh Perspectives
In February, we began spotlighting the talented and passionate members of our Advisory Committee across our social media channels, and we're excited to continue to introduce new collaborators who have recently joined the AdCom. So far, we've given a warm NICA welcome to Mike Cooper and Dr. Colin Edgerton from the American Rheumatology Network as well as Marissa Shackleton, Executive Director of the Elliot Lewis Center. Keep your eye on our social media for more intros!
Spotlight: Infusion Center Successfully Operates Early Pop-Up for COVID-19 Antibody Therapies
Early this year, NICA had the pleasure of introducing MPP Infusion Centers to NCTTRAC, an organization in Texas that helped MPP initiate their incredibly successful pop-up model. This very special Infusion Center Spotlight offers an in-depth look at the process of transitioning a standard ambulatory infusion center to a pop-up site for administering COVID-19 antibody therapeutics.
5 Organizations Pull Up a Chair:
In March, we welcomed several new organizations as NICA Industry, Strategic, and Preferred partners. These organizations are dedicated to providing supplies, devices, goods, and services that help providers better serve their patients. Their support is critical to achieving our mission to be the nation’s voice for non-hospital, community-based infusion providers. To learn more about the organizations and check out the discounts available to our Provider Members, click the button below.
Advocacy Win for NICA Means a Win for All Spravato Patients
We are excited to share a huge WIN on behalf of Spravato patients and providers! After significant pushback from NICA, Janssen Inc., and practices such as Dent Neurologic Institute, CMS released notice of technical corrections for its 2021 reimbursement rates. As the only provider-administered nasal spray for treatment-resistant depression, it is imperative that we ensure providers can remain economically viable when treating Spravato patients.
Extra, Extra - Read All About It
We’ve added a press page to the NICA website. After all the buzz surrounding the EUA of monoclonal antibody therapies for the treatment of COVID-19, NICA was mentioned several times in the press in regard to our resource, the COVID-19 Antibody Treatment Locator. If you’d like to read more, visit our website and hit the About Us drop down and navigate to “Press”. Or click the button below.
Back in Stock! Huge Win for TEPEZZA Patients
NICA has been hard at work advocating on behalf of TEPEZZA patients affected by the current supply disruption. We met with 10 offices across both parties and chambers, wrote letters to and spoke with the FDA, and had ongoing meetings with Horizon leadership to help pressure the FDA to resume production. We have recently learned that the FDA approved an updated manufacturing arrangement and production is now expected to provide sufficient drug supply to meet the current demand while longer-term production is scaled-up to meet future demand.